Download PDF
Thromb Haemost 1971; 25(03): 447-459
DOI: 10.1055/s-0038-1654319
Originalarbeiten – Original Articles – Travaux Originaux
Schattauer GmbH

Factor IX-Inhibitors

Report of Two Cases and a Study of the Biological, Chemical and Immunological Properties of the Inhibitors
K Lechner
1   First Department of Medicine, University of Vienna (Head: Prof. Dr. E. Deutsch)
› Author AffiliationsThis work has been supported by a grant from the “Österreichische Fonds zur Förderung der wissenschaftlichen Forschung” Nr. 703 and 900.
Further Information

Publication History

Publication Date:
28 June 2018 (online)

Also available at
    Permissions and Reprints

Summary

1. Two patients with severe hemophilia B and an acquired inhibitor against factor IX are described.

2. The inhibitors inactivate factor IX irreversibly. The speed of inactivation is very fast and cannot slowed down by dilution of the inhibitor or by lowering of the incubation temperature. Factor IX of serum is inactivated to a higher degree than factor IX of plasma. Factor IX inhibitors are more sensitive to dilution than factor VIII inhibitors.

3. The inhibitor protein is eluted from the Sephadex G-200 column with the G-peak. On Chromatography on DEAE-cellulose two activity peaks are obtained.

4. Immunologically the inhibitors belong predominantly to the immune globulins of the G-class, but it cannot be excluded that the activity is also associated with IgA. As light chains kappa chains were found in one case.

 

  • References

  • 1 Andersen B. R, Trowp S. B. Gamma G-antibody to human antihemophilic globulin (factor VIII). J. Immunol 100: 175 1968;
    PubMedSearch in Google Scholar
  • 2 Bergna L. J, Pavlowsky A. Classification of hemophiliacs with development of an anticoagulant. Actahemat. (Basel.) 16: 247 1956;
    PubMedSearch in Google Scholar
  • 3 Breckenridge R. T. VIIth congress of the world federation of hemophilia Baden. 1970 (discussion).
    PubMedSearch in Google Scholar
  • 4 Fanti P, Sawers R. J. Anticoagulant specificity and physiologically inactive beta-prothromboplastin. Nature (Lond.) 177: 1233 1956;
    CrossrefPubMedSearch in Google Scholar
  • 5 Fantl P, Sawers R. J, Marr A. G. Investigation of a hemorrhagic disease due to beta-prothromboplastin deficiency complicated by a specific inhibitor of thromboplastin formation. Aust. Ann. Med 05: 163 1956;
    PubMedSearch in Google Scholar
  • 6 Goldstein R, Gelfand M, Sanders M, Rosen R. Anticoagulant appearing in plasma thromboplastin component (PTC) deficiency (Abstr.). J. clin. Invest 35: 707 1956;
    PubMedSearch in Google Scholar
  • 7 Hardisty R. M. A naturally occuring inhibitor of Christmas factor (factor IX). Thrombos. Diathes. haemorrh. (Stuttg.) 08: 67 1962;
    PubMedSearch in Google Scholar
  • 8 Lechner K. A new type of coagulation inhibitor. Thrombos. Diathes. haemorrh. (Stuttg.) 21: 482 1969;
    PubMedSearch in Google Scholar
  • 9 Lechner K. Inhibitors in iso- and autoimmune disease. I. Conf. Thrombosis and Hemostasis (Montreux) 1970. Thrombos. Diathes. haemorrh. (Stuttg). 1971 (In press.)
    PubMedSearch in Google Scholar
  • 10 Lechner K. Immunologisch bedingte Koagulopatien. Thrombos. Diathes. haemorrh. (Stuttg.) 34: 33 1969;
    PubMedSearch in Google Scholar
  • 11 Lewis J. H, Ferguson J. H, Arends T. Hemorrhagic disease with circulating inhibitors of blood clotting: anti-AHF and anti-PTC in eight cases. Blood 11: 846 1956;
    PubMedSearch in Google Scholar
  • 12 Margolius A, Jackson D. P, Ratnoff O. D. Circulating anticoagulants: a study of 40 cases and a review of the literature. Medicine (Baltimore.) 40: 145 1961;
    CrossrefPubMedSearch in Google Scholar
  • 13 O’Brien J. R. Un inhibiteur de la maladie de Christmas. Rév. hémat 12: 294 1957;
    PubMedSearch in Google Scholar
  • 14 Roberts H. R, Gross G. P, Webster W. P, Dejanow I. I, Penick G. D. Acquired inhibitors to plasma factor IX: A study of their induction, properties and neutralisation. Amer. J. med. Sci 251: 43 1960;
    PubMedSearch in Google Scholar
  • 15 Shajpiro S. S. The immunological character of acquired inhibitors of antihemophilic globulin (F VIII) and the kinetics of their interaction with factor VIII. J. clin. Invest 46: 147 1967;
    CrossrefPubMedSearch in Google Scholar
  • 16 Soulier J. P, Larrieu M. J. Differentiation of hemophilia into two groups. A study of thirty-three cases. New Engl. J. Med 249: 547 1953;
    PubMedSearch in Google Scholar
  • 17 Spaet T. H, Garner E. S. Resistance to transfusion in hemophilia and deuterohemophilia. Stanf. med. Bull 13: 188 1955;
    PubMedSearch in Google Scholar